<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00406003</url>
  </required_header>
  <id_info>
    <org_study_id>PCR104074</org_study_id>
    <nct_id>NCT00406003</nct_id>
  </id_info>
  <brief_title>Single Dose Pharmacokinetic (PK) Study Of Paroxetine CR(12.5-37.5mg) In Healthy Chinese Subjects</brief_title>
  <official_title>A Randomized, Open, Three-period Crossover Study to Compare the Pharmacokinetic Profile of Paroxetine After Single Dosing of Each Enteric-coated Geomatrix Control Release Tablet Strength (12.5, 25, 37.5mg) in Healthy Chinese Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>GlaxoSmithKline</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>GlaxoSmithKline</source>
  <brief_summary>
    <textblock>
      The study was designed to describe the relationship between dose and pharmacokinetic
      parameters of paroxetine over the range of proposed dosage strengths of the paroxetine CR
      tablet (12.5 to 37.5 mg) as well as safety profile
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">March 24, 2006</start_date>
  <completion_date type="Actual">April 26, 2006</completion_date>
  <primary_completion_date type="Actual">April 26, 2006</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To obtain pharmacokinetic parameters of paroxetine paroxetine CR tablet (12.5 to 37.5 mg) in healthy Chinese subjects</measure>
    <time_frame>Up to 32 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>To describe Safety profile of healthy subjects when dosed with paroxetine controlled release</measure>
    <time_frame>Up to 32 days</time_frame>
  </secondary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Actual">6</enrollment>
  <condition>Depressive Disorder</condition>
  <arm_group>
    <arm_group_label>Subjects receiving treatment sequence ABC</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Eligible subjects will receive treatment sequence ABC; A= paroxetine 12.5 milligrams, B= paroxetine 25 milligrams, and C= paroxetine 37.5 milligrams separated by a wash-out period of 10 days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Subjects receiving treatment sequence BAC</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Eligible subjects will receive treatment sequence BAC; B= paroxetine 25 milligrams, A= paroxetine 12.5 milligrams and C= paroxetine 37.5 milligrams separated by a wash-out period of 10 days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Subjects receiving treatment sequence CBA</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Eligible subjects will receive treatment sequence CBA; C= paroxetine 37.5 milligrams, B= paroxetine 25 milligrams and A= paroxetine 12.5 milligrams separated by a wash-out period of 10 days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Subjects receiving treatment sequence BCA</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Eligible subjects will receive treatment sequence BCA; B= paroxetine 25 milligrams, C= paroxetine 37.5 milligrams and A= paroxetine 12.5 milligrams separated by a wash-out period of 10 days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Subjects receiving treatment sequence CAB</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Eligible subjects will receive treatment sequence CAB; C= paroxetine 37.5 milligrams, A= paroxetine 12.5 milligrams and B= paroxetine 25 milligrams separated by a wash-out period of 10 days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Subjects receiving treatment sequence ACB</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Eligible subjects will receive treatment sequence ACB; A= paroxetine 12.5 milligrams, C= paroxetine 37.5 milligrams and B= paroxetine 25 milligrams separated by a wash-out period of 10 days.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Paroxetine controlled release tablet</intervention_name>
    <description>Paroxetine will be given as single dose, controlled release tablet with dosing strengths of 12.5, 25 and 37.5 milligrams in fasted state separated by a wash-out period of 10 days.</description>
    <arm_group_label>Subjects receiving treatment sequence CBA</arm_group_label>
    <arm_group_label>Subjects receiving treatment sequence CAB</arm_group_label>
    <arm_group_label>Subjects receiving treatment sequence BAC</arm_group_label>
    <arm_group_label>Subjects receiving treatment sequence ABC</arm_group_label>
    <arm_group_label>Subjects receiving treatment sequence BCA</arm_group_label>
    <arm_group_label>Subjects receiving treatment sequence ACB</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:

          -  19-45 years healthy Chinese

          -  Body weight &gt; 50 kg

          -  BMI between 19-25

          -  serological negative for HIV, syphilis and hepatitis B and C

          -  no abnormalities in ECG

          -  Female with negative pregnancy and male has no plan to have a child during and 3
             months after the study.

        Exclusion criteria:

          -  History of chronic physical/mental disease, current disease and concomitant medication
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>GSK Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>GlaxoSmithKline</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Beijing</city>
        <zip>100730</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <link>
    <url>https://gsk-clinicalstudyregister.com/study/PCR104074?search=study&amp;study_ids=PCR104074#rs</url>
    <description>Results for study PCR104074 can be found on the GSK Clinical Study Register.</description>
  </link>
  <verification_date>September 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 30, 2006</study_first_submitted>
  <study_first_submitted_qc>November 30, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 4, 2006</study_first_posted>
  <last_update_submitted>September 27, 2017</last_update_submitted>
  <last_update_submitted_qc>September 27, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">September 29, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>BRL029060/Paroxetine CR</keyword>
  <keyword>pharmacokinetics</keyword>
  <keyword>safety</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Depressive Disorder</mesh_term>
    <mesh_term>Depression</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Paroxetine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

